Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
To characterize the defects in β-cell function in subjects with impaired fasting glucose (IFG) and compare the results to impaired glucose tolerance (IGT) and normal glucose tolerance (NGT) subjects, β-cell glucose sensitivity and rate sensitivity during the oral glucose tolerance test were measured with the model by Mari in 172 Mexican Americans. A subgroup (n = 70) received a 2-h hyperglycemic clamp (+125 mg/dL), and first- and second-phase insulin secretion were quantitated. Compared with NGT, subjects with IFG and IGT manifested a decrease in β-cell glucose sensitivity; IFG subjects, but not IGT subjects, had decreased β-cell rate sensitivity. In IFG subjects, the defect in β-cell glucose sensitivity was time dependent, began to improve after 60 min, and was comparable to NGT after 90 min. The incremental area under the plasma C-peptide concentration curve during the first 12 min of the hyperglycemic clamp (ΔC-pep[AUC]0–12) was inversely related with the increase in FPG concentration (r = −36, r = 0.001), whereas ΔC-pep[AUC]15–120 positively correlated with FPG concentration (r = 0.29, r < 0.05). When adjusted for the prevailing level of insulin resistance, first-phase insulin secretion was markedly decreased in both IFG and IGT, whereas second-phase insulin secretion was decreased only in IGT. These results demonstrate distinct defects in β-cell function in IFG and IGT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These results demonstrate a definite beta-cell defect in IFG and IGT.[21]”
From Postprandial Reactive Hypoglycemia (2019) · cites this paper as [21]
In the citing paper
“β-cell dysfunction is present both in people with isolated IFG and isolated IGT. IFG people have severely impaired early insulin response during OGTT but their insulin secretion improves during the second phase of the OGTT. In contrast, IGT people present with impaired early and late phase insulin secretion.38,39,50”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [50]
In the citing paper
“These findings suggest distinct pathophysiological mechanisms of isolated IFG and isolated IGT although the clinical relevance of these observations requires further clarification.”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [50]
In the citing paper
“IFG is characterized primarily by impaired hepatic insulin sensitivity and a decrease in the first-phase insulin response”
From The Vasculature in Prediabetes (2018) · cites this paper as [13]
In the citing paper
“IGT is characterized by impaired muscle insulin sensitivity as well as early and late phase insulin responses.”
From The Vasculature in Prediabetes (2018) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 2×
“The glucose infusion rate divided by the mean plasma insulin concentration during the hyperglycemic clamp (0–120), an index of insulin sensitivity (26), was markedly reduced by 54% in subjects with IGT (P , 0.”
BackgroundMethodSelf-citationReport of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Writing committee, Unwin, N., Shaw, J., Zimmet, P., & Alberti, K. G. M. M. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00835.x · Cited by 1,108
Abdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Self-citationGerstein, H. C., Santaguida, P., Raina, P., Morrison, K. M., Balion, C., Hunt, D., Yazdi, H., & Booker, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.05.004 · Cited by 575
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540 · cited 5×
“b-Cell glucose sensitivity, rate sensitivity, and the potentiation factor were calculated with the model by Mari (12,22).”
MethodSelf-citationAbdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500 · cited 2×
“This can be explained by 1) the time-related improvement in b-cell glucose sensitivity during the 60–120 min time period; 2) the increase in potentiation factor (Table 2); and 3) normal to near-normal muscle insulin sensitivity (9).”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Conversely, improving glycemic control in type 2 diabetic subjects with insulin therapy improves b-cell function (27), and experimental studies in animals (28–30) have reported that a small rise (16 mg/dL) in FPG concentration is associated with a marked inhibition of glucose-stimulated insulin secretion, whereas corr…”
BackgroundEffect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.
Rossetti, L., Shulman, G. I., Zawalich, W., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113157 · Cited by 330 · cited 1×
“Conversely, improving glycemic control in type 2 diabetic subjects with insulin therapy improves b-cell function (27), and experimental studies in animals (28–30) have reported that a small rise (16 mg/dL) in FPG concentration is associated with a marked inhibition of glucose-stimulated insulin secretion, whereas corr…”
BackgroundSelf-citation
Cited by
Items 101–127 of 127
Liang, Y., Gong, J., Chen, X., Li, G., Lin, X., He, J., Chen, Y., & Wu, R. (2022) · Ginekologia Polska · doi:10.5603/gp.a2022.0007 · Cited by 5
Toppala, S., Ekblad, L. L., Viitanen, M. H., Rinne, J. O., & Jula, A. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220894 · Cited by 3
Xu, X., Wang, D., Jaffar, S. S., Alam, U., Qiu, S., Xie, B., Sun, Z., & Garrib, A. V. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01289-y · Cited by 3
“IGT is associated with more severe insulin resistance and beta-cell dysfunction [34–36].”
Pancreatic β‐cell Function is Higher in Morning Versus Intermediate Chronotypes With Obesity
Malin, S. K., Remchak, M. E., Heiston, E. M., Fabris, C., & Shah, A. M. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70064 · Cited by 3
“This is important because people with obesity have reduced early and late phase insulin secretion, thereby raising the risk of type 2 diabetes [17].”
Health implications of prediabetes and the role of trace elements in insulin resistance
Amer, H. M., Aboelyazed, S., Elshafeey, F., & Elhalawany, S. H. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00811-9 · Cited by 3
“Several studies have indicated a link between prediabetes and a higher risk of chronic kidney disease and early nephropathy, as indicated by markers like urinary albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR) [80, 81].”
Zhang, X., Zhou, X., Han, X., Fu, Z., Wang, L., Li, Y., & Ji, L. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0107 · Cited by 3
Alteraciones glucémicas en los pacientes con enfermedad renal crónica
De’Marziani, G., Pujol, G. S., Obregón, L. M., Morales, E., González, C. D., Paganti, L. G., Cacciagiú, L. D., López, G., Schreier, L. E., & Elbert, A. E. (2016) · Nefrología · doi:10.1016/j.nefro.2015.10.011 · Cited by 1
“Edad (años) 67,84 (12,80) 58,64 (17,57) 46,91 (14,02) <0,01 <0,01 <0,01 Glucemia basal (mg/dL) 105,49 (19,44) 90,83 (17,68) 93,62 (12,86) <0,01 NS <0,01 Glucemia 120 min (mg/dL) 145,49 (59,29) 133,17 (47,81) 115,12 (46,58) NS NS <0,05 Glucemia basal previa (mg/dL) 104,73 (13,74) 97,49 (20,18) 96,47 (10,50) NS NS <0,05…”
Serum Vitamin D Associated with Insulin Secretory Function in Impaired Fasting Glucose Subjects
Rahman, A. K. M. S., Sohel, M. A., Bhuiyan, F. R., Ashrafee, F. A. S., Hossain, M. K., Islam, S. F., Ali, M. I., & Zinnat, R. (2019) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2019.71008 · Cited by 1
A metformin helye a prediabetes kezelésében – ahogyan ma látjuk
Winkler, G. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.13 · Cited by 1
Glycaemic changes in patients with chronic kidney disease
De’Marziani, G., Pujol, G. S., Obregón, L. M., Morales, E. M., González, C. D., Paganti, L. G., Cacciagiú, L. D., Lopez, G. I., Schreier, L. E., & Elbert, A. E. (2016) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2016.04.001 · Cited by 1
Ignell, C. (2015) · Lund University Publications (Lund University) · Cited by 1
Félix‐Martínez, G. J., Leehan, J. A., Ávila-Pozos, R., & Fernández, J. R. G. (2014) · Revista Mexicana de Ingeniería Biomédica · Cited by 2
Family history of diabetes: a risk analysis
Mataloto, P. A. M. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
The Role of Sox17 in Normal and Pathological Beta Cell
Jonatan, D. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Bile Acids and FGF19 in the Remission of Type 2 Diabetes After Sleeve Gastrectomy and Gastric Bypass
Nemati, R. (2017) · Tuwhera (Auckland University of Technology) · Cited by 1
Gabriel, R., Boukichou-Abdelkader, N., Acosta, T., Gilis‐Januszewska, A., Gómez‐Huelgas, R., Makrilakis, K., Kamenov, Z. A., Paulweber, B., Satman, İ., Djordjević, P., et al. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.60692/fq40h-7gd41
Diagnosi dell’ipoglicemia nell’adulto non diabetico
Gullo, D., Magliozzo, M., Belfiore, A., & Arpi, M. L. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00925-1 · Cited by 1
Nandhini, L. P., Kamalanathan, S., & Sahoo, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_6 · Cited by 1
Approach to Prevent Progression from Prediabetes to Type 2 Diabetes
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407625.ch07
Efficacy of metformin in a patient with prediabetes in the framework of pregravity preparation
Алексеевна, Б. Г., Zhaburina, M. V., & Batrak, N. V. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-156
Vazzana, A., Giannatiempo, V., & Dei, A. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01623-y
“Questo riflette un’insulino-resistenza periferica con ridotta captazione del glucosio da parte dei tessuti periferici e un deficit nella risposta secretoria delle β -cellule [11].”
Prediabetes is a window of opportunity for preventive interventions. Part 1
Adasheva, T. V., Евгеньевна, Г. Е., Игоревна, Ф. Е., & Георгиевна, Л. Е. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-407
Toppala, S. (2022) · UTUPub (University of Turku)
Bahadoran, Z., Nozari, Z., & Azizi, F. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01923-6
Wu, L., Fan, G., Zhang, L., Bi, J., Peng, J., Liu, Q., Fang, Q., Song, L., Zheng, L., Chen, S., et al. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01109-0
“This risk hierarchy mirrors the progressive deterioration in β-cell function and insulin resistance seen in the natural history of T2DM, [31, 32] suggesting that combined hyperglycemia reflects a more advanced stage of metabolic decompensation.”
Niu, S., Zhang, L., Deng, Z., Wu, J., & Wang, Y. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s634304
“By 34–36 Both subtypes exhibit β-cell defects: IFG shows prominent impairment of early-phase insulin secretion, while IGT demonstrates combined early-and late-phase secretory insufficiency.”
Mechanisms of Hepatic Insulin Resistance and Its Contribution to the Pathogenesis of Type 2 Diabetes
Onyango, A. N. (2026) · Comprehensive physiology · doi:10.1002/cph4.70285
Metadata
- Authors
- Kanat, M., Mari, A., Norton, L., Winnier, D., DeFronzo, R. A., Jenkinson, C., & Abdul-Ghani, M. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, Texas
- Corresponding author
- Abdul-Ghani, Muhammad A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-01-17
- Volume
- 61
- Issue
- 2
- Pages
- 447-453
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3266412
- OpenAlex
- W2106830005
- Cited by
- 122
- References
- 35
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 8 · 2020: 13 · 2019: 9 · 2018: 13 · 2017: 6 · 2016: 12 · 2015: 6 · 2014: 14 · 2013: 7 · 2012: 5
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK079195)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- beta-cell function, impaired fasting glucose, impaired glucose tolerance, beta-cell glucose sensitivity, first-phase insulin secretion, second-phase insulin secretion, C-peptide, hyperglycemic clamp, oral glucose tolerance test, insulin resistance, prediabetes, Mexican Americans
- MeSH terms
- Adult, Blood Glucose, Fasting, Female, Glucose Tolerance Test, Humans, Insulin Resistance, Male, Middle Aged, Glucose Intolerance, Area Under Curve, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.